Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Has Gilead Sciences (GILD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Gilead Sciences is a member of the Medical sector.

NASDAQ GILD opened at $109.95 on Friday. The business has a 50 day simple moving average of $95.41 and a 200 day simple moving average of $88.63. Gilead Sciences has a 52-week low of $62.07 and a ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other stocks that analysts think will go up. The S&P 500 index touched an all-time high ...

Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...

Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $106.69. Gilead Sciences ( NASDAQ:GILD – Get Free Report ) last posted its earnings results on Tuesday, February 11th.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other Renaissance Technologies portfolio’s top stock picks. The American quant hedge ...

Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...